The Predictive Low Glucose Management System in Prevention of Clinically Significant Hypoglycemia in Type 1 Diabetes. A Preliminary Study Identifying the Most Common Events Leading Up to Hypoglycemia During Insulin Pump Therapy

Abstract

Background/aim Prevention of hypoglycemia remains a major challenge in diabetic management, despite the introduction of modern insulin pumps in daily clinical practice. The Low Glucose Suspend (LGS) and the newer Predictive Low Glucose Management (PLGM) systems incorporated in the Medtronic insulin pumps have shown promising results in prevention of hypoglycemia. Our aim was to evaluate the effect of the 2 systems relative to the frequency of clinically significant hypoglycemia in Type 1 diabetes (T1DM). In addition, we investigated the events preceding clinically significant hypoglycemia episodes.

Methods A cross-sectional study was conducted in 30 T1DM patients using the MiniMed 640G vs. 30 using the MiniMed Veo sensor-augmented insulin pump. All data was recorded during patients’ normal daily activity and living conditions. The patients were matched for age and duration of diabetes.

Results PLGM use was associated with lower incidence of clinically significant hypoglycemia (1.9±1.4 vs. 3.6±1.9 episodes per week), along with reduced exposure to hypoglycemia. The data indicated that both pump systems are effective in preventing severe hypoglycemic episodes. In both groups the most common events preceding hypoglycemic episodes included adjustment of hyperglycemia, basal rate increase and miscalculation of carbohydrates.

Conclusions The results indicated that the use of the Minimed 640G pump system can help reduce the frequency of clinically significant hypoglycemia. Management of hyperglycemia must be addressed in diabetes education programs in order to encourage proper adjustment of high blood glucose levels. Future studies would be useful in exploring the details of the events preceding hypoglycemia episodes in insulin pump users.

Key words

insulin pumps - hypoglycemia - predictive low glucose management system

Publication History

Received: 22 January 2019
Received: 21 March 2019

Accepted: 03 April 2019

Article published online:
15 April 2019

• References

• 1 Schiel R, Burgard D, Perenthaler T. et al. Use and Effectiveness of Continuous Subcutaneous Insulin Infusion (CSII) and Multiple Daily Insulin Injection Therapy (MIT) in Children, Adolescents and Young Adults with Type 1 Diabetes Mellitus. Exp Clin Endocrinol Diabetes. 2016; 124: 99-104
• 2 Weiss R, Garg SK, Bergenstal RM. et al. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery. J Diabetes Sci Technol 2015; 9: 1016-1020
• 3 Polonsky WH, Hessler D, Ruedy KJ. et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: Further findings from the diamond randomized clinical trial. Diabetes Care 2017; 40: 736-741
• 4 Yeoh E, Choudhary P, Nwokolo M. et al. Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: A systematic review and meta-analysis. Diabetes Care 2015; 38: 1592-1609
• 5 Karges B, Schwandt A, Heidtmann B. et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA 2017; 318: 1358-1366
• 6 Bergenstal RM, Klonoff DC, Garg SK. et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369: 224-232
• 7 Choudhary P, Olsen BS, Conget I. et al. Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016; 18: 288-291
• 8 Biester T, Kordonouri O, Holder M. et al. “Let the Algorithm Do the Work”: Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients. Diabetes Technol Ther 2017; 19: 173-182
• 9 Pinsker JE, Dassau E. Predictive low-glucose suspend to prevent hypoglycemia. Diabetes Technol Ther 2017; 19: 271-276
• 10 Choudhary P, Shin J, Wang Y. et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011; 34: 2023-2025
• 11 Agrawal P, Welsh JB, Kannard B. et al. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol 2011; 5: 1137-1141
• 12 Zhong A, Choudhary P, McMahon C. et al. Effectiveness of automated insulin management features of the minimed® 640g sensor-augmented insulin pump. Diabetes Technol Ther 2016; 18: 657-663
• 13 Ly TT, Nicholas JA, Retterath A. et al. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: A randomized clinical trial. JAMA 2013; 310: 1240-1247
• 14 International Hypoglycaemia Study Group . Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: A joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40: 155-157
• 15 World Medical Association: World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194
• 16 Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697-703
• 17 Zaccardi F, Dhalwani NN, Webb DR. et al. Global burden of hypoglycaemia-related mortality in 109 countries, from 2000 to 2014: an analysis of death certificates. Diabetologia 2018; 61: 1592-1602
• 18 Zaccardi F, Webb DR, Kurl S. et al. Inverse association between fasting plasma glucose and risk of ventricular arrhythmias. Diabetologia. 2015; 58: 1797-1802
• 19 Battelino T, Nimri R, Dovc K. et al. Prevention of hypoglycemia with predictive low glucose insulin suspension in children with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2017; 40: 764-770
• 20 Scaramuzza AE, Arnaldi C, Cherubini V. et al. Use of the predictive low glucose management (PLGM) algorithm in Italian adolescents with type 1 diabetes: CareLink™ data download in a real-world setting. Acta Diabetol. 2017; 54: 317-319
• 21 Buckingham BA, Raghinaru D, Cameron F. et al. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care. 2015; 38: 1197-1204
• 22 Steineck I, Ranjan A, Nørgaard K. et al. Sensor-augmented insulin pumps and hypoglycemia prevention in type 1 diabetes. J Diabetes Sci Technol 2017; 11: 50-58
• 23 Choudhary P, Amiel SA. Hypoglycaemia in type 1 diabetes: Technological treatments, their limitations and the place of psychology. Diabetologia. 2018; 61: 761-769
• 24 Singh H, Gonder-Frederick L, Schmidt K. et al. Assessing hyperglycemia avoidance in people with Type 1 diabetes. Diabetes Management. 2014; 4: 263-271
• 25 Ritholz M. Is Continuous glucose monitoring for everyone? consideration of psychosocial factors.. Diabetes Spectrum 2008; 21: 287-289
• 26 Abraham MB, de Bock M, Paramalingam N. et al. Prevention of insulin-induced hypoglycemia in type 1 diabetes with predictive low glucose management system. Diabetes Technol Ther 2016; 18: 436-443
• 27 Ramotowska A, Golicki D, Dżygało K. et al. The effect of using the insulin pump bolus calculator compared to standard insulin dosage calculations in patients with type 1 diabetes mellitus - systematic review. Exp Clin Endocrinol Diabetes 2013; 121: 248-254